Kevin Feeley Sells 922 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 922 shares of GeneDx stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the sale, the chief financial officer now directly owns 5,446 shares of the company’s stock, valued at approximately $515,845.12. This represents a 14.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $286,124.00.

GeneDx Price Performance

Shares of GeneDx stock opened at $92.08 on Thursday. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a twelve month low of $7.72 and a twelve month high of $115.60. The business has a 50-day moving average price of $84.02 and a 200 day moving average price of $68.85. The firm has a market cap of $2.58 billion, a PE ratio of -46.98 and a beta of 1.90.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million during the quarter, compared to analyst estimates of $82.24 million. Sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. MCF Advisors LLC boosted its holdings in shares of GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after purchasing an additional 316 shares during the last quarter. Global Retirement Partners LLC acquired a new position in GeneDx in the fourth quarter valued at approximately $28,000. Lazard Asset Management LLC acquired a new position in GeneDx in the fourth quarter valued at approximately $35,000. Finally, Comerica Bank acquired a new position in GeneDx in the fourth quarter valued at approximately $50,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. The Goldman Sachs Group lifted their price objective on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen lifted their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.